Inaxaplin is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Phase III program in Focal Segmental Glomerulosclerosis (FSGS). According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Inaxaplin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Inaxaplin is expected to reach an annual total of $236 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Inaxaplin is under development for the treatment of APO-L1 mediated kidney diseases including focal segmental glomerulosclerosis (FSGS). The drug candidate is administered through oral route. It acts by targeting APO-L1 function.
Vertex Pharmaceuticals Overview
Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.
The company reported revenues of (US Dollars) US$8,930.7 million for the fiscal year ended December 2022 (FY2022), an increase of 17.9% over FY2021. The operating profit of the company was US$4,307.4 million in FY2022, compared to an operating profit of US$2,782.1 million in FY2021. The net profit of the company was US$3,322 million in FY2022, compared to a net profit of US$2,342.1 million in FY2021.
For a complete picture of Inaxaplin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.